Market Research Report
Global Veterinary Antibiotics Market -2019-2026
|Published by||DataM Intelligence||Product code||913722|
|Published||Content info||130-180 Pages
Delivery time: 1-2 business days
|Global Veterinary Antibiotics Market -2019-2026|
|Published: October 19, 2019||Content info: 130-180 Pages||
Antibiotics are the most important tools in a veterinarian's toolbox as they cure bacterial disease in animals, without animals suffer or die by devastating diseases like anthrax or pneumonia. The use of antibiotics in animal agriculture helps to grow the demand for safe livestock-derived food such as meat, milk and eggs.
The global veterinary antibiotics market was worth $ XX billion in 2018 and is forecasted to reach $ XX billion by 2026, at a CAGR of XX% during the forecast period.
Increasing use of antibiotics in livestock is one of the factor fueling the global veterinary antibiotics market.
According to Food and Drug Administration (FDA), around 12.3 million pounds of medically important antibiotics were sold for use in U.S. livestock and poultry in 2017.
In the US, livestock antibiotic use continues to account for about 64% of the sales of medically important antibiotics.
In the United States around 80% of all antibiotics are given to cows, pigs, and chickens to make them grow more quickly or as a cheap alternative to keeping them healthy. In 2013, more than 131,000 tons of antibiotics were used in food animals worldwide, and it is expected to rise by 200,000 tons in 2030.
In U.K the antibiotic use in pigs about five times higher than in Denmark (46 mg/kg PCU) and the Netherlands (53 mg/kg PCU) and about 25 times higher than in Sweden (11 mg/kg PCU).
Based on product type the global market for veterinary antibiotics is broadly segmented as by anti-parasitic, anti-bacterial, non-steroidal anti-inflammatory drug, and others.
Currently anti-parasitic is the dominant segment and it accounts for approximately XX% of the market, due to the launch of new products and facility expansion for anti-parasitic.
For instance, in January 2019, Bayer Animal Health have introduced Coraxis (moxidectin) Topical Solution for Dogs, a prescription-only, monthly transdermal product that prevents heartworm disease and treats and controls hookworms, roundworms, and whipworms in dogs. Coraxis is a unique addition to the veterinarian's anti-parasite toolbox.
In June 2018, UC San Diego have introduced new center for anti-parasitic drug discovery and development to address this unmet need in global health. UC San Diego researchers use robotic technology to screen hundreds of thousands of chemical compounds from a variety of sources including drugs abandoned by pharmaceutical companies and marine natural products. Further test the compounds in laboratory experiments and animal health.
The global veterinary antibiotics market is segmented into North America, Europe, Asia Pacific, South America and ROW.
North America is dominating the global veterinary antibiotics market, due to the increasing use of antibiotics in livestock.
For instance, According to government estimates, approximately 30 million pounds of antibiotics are sold for use in industrial animal agriculture. It is four times the amount used by the health care sector, and this number is growing.
According to the United States Food and Drug Administration (FDA), the annual sales of antibiotics for food-producing animals is increased every year, and by 26% in total.
The U.S sales of the critically important fluoroquinolones antibiotics was 20 tonnes in 2015, a 16% increase from 2014. In 2015, total sales of medically important antibiotics in the US was 9,702 tonnes.
According to the United States Food and Drug Administration (FDA), in 2015, 74% of farm-animal antibiotics were administered in feed and 21% in drinking water.
The new technology development and product launch is driving the global veterinary antibiotics market.
For instance, in August 2018, Bayer have introduced i-COWNT BRD a novel online comparison tool that is designed to help veterinarians make more informed treatment decisions for bovine respiratory disease (BRD). It is based on an independent mixed treatment comparison meta-analysis of BRD-treatment studies. I-COWNT BRD simplifies the analysis of scientific data to enable veterinarians to choose the most efficacious antibiotic for treatment.
In May 2016, Elanco Animal Health have introduced Inteprity, a first-in-class, animal-use only, in-feed antibiotic developed for the prevention of mortality caused by necrotic enteritis associated with Clostridium perfringens in broiler chickens.